An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step

被引:11
作者
Barbouche, R
Decroly, E
Kieny, MP
Fenouillet, E
机构
[1] Fac Med Nord, CNRS, Marseille, France
[2] Inst Natl Sante & Rech Med, U372, Marseille, France
[3] Inst Natl Sante & Rech Med, U74, Strasbourg, France
关键词
HIV Env; processing; membrane fusion; anti-HIV peptide; cleavage sequence;
D O I
10.1006/viro.2000.0368
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
CLIV is a multiple antigen peptide ([PTKAKRRVVQREKR](4)-K-2-K-beta A) that encompasses the cleavage region of the human immunodeficiency virus type 1 (HIV-I) envelope precursor. II displays an antiviral activity against HIV-1 and HIV-2 and inhibits HIV-1 Env-mediated cell-to-cell fusion. This effect has previously been attributed to interference with Env processing, resulting in the expression of a nonfusogenic envelope [Virology ( 1998) 247, 137]. However, we show here that CLIV does not alter the status of Env cleavage at steady state. Using various aggregation/syncytium assays that allow us to discriminate between gp120/CD4 binding and binding followed by gp41-mediated fusion, we demonstrate that CLIV inhibits a step of the cell-to-cell fusion process after CD4 binding. We demonstrate also that CLIV binds at 37 degrees C to a single class of protein present at the CD4(+) cell surface (Scatchard analysis: K-d = 8 nM; B-max = 10(4) sites/cell) and that the fusion inhibition activity seems to correlate with binding to this proteic component. In contrast, CLIV interacts with neither membrane-inserted nor CD4-associated Env. We therefore propose that CLIV interferes after Env/CD4 binding with a step of the membrane fusion process that may involve the C-terminal domain of gp120. (C) 2000 Academic Press.
引用
收藏
页码:169 / 177
页数:9
相关论文
共 34 条
[1]   VACCINIA VIRUS VECTORS FOR STUDY OF MEMBRANE-FUSION MEDIATED BY HUMAN-IMMUNODEFICIENCY-VIRUS ENVELOPE GLYCOPROTEIN AND CD4 [J].
ASHORN, P ;
BERGER, EA ;
MOSS, B .
METHODS IN ENZYMOLOGY, 1993, 221 :12-18
[2]   IDENTIFICATION OF THE U-937 MEMBRANE-ASSOCIATED PROTEINASE INTERACTING WITH THE V3 LOOP OF HIV-1 GP120 AS CATHEPSIN-G [J].
AVRIL, LE ;
DIMARTINOFERRER, M ;
PIGNEDE, G ;
SEMAN, M ;
GAUTHIER, F .
FEBS LETTERS, 1994, 345 (01) :81-86
[3]  
Barbouche R, 1998, J PEPT SCI, V4, P479, DOI 10.1002/(SICI)1099-1387(199812)4:8<479::AID-PSC167>3.3.CO
[4]  
2-9
[5]   An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on env fusogenicity through the presence of a functional cleavage sequence [J].
Barbouche, R ;
Sabatier, JM ;
Fenouillet, E .
VIROLOGY, 1998, 247 (02) :137-143
[6]   Relationships between the anti-HIV V3-derived peptide SPC3 and lymphocyte membrane properties involved in virus entry:: SPC3 interferes with CXCR4 [J].
Barbouche, R ;
Papandréou, MJ ;
Miquelis, R ;
Guieu, R ;
Fenouillet, E .
FEMS MICROBIOLOGY LETTERS, 2000, 183 (02) :235-240
[7]   MUTATIONAL ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENV GENE-PRODUCT PROTEOLYTIC CLEAVAGE SITE [J].
BOSCH, V ;
PAWLITA, M .
JOURNAL OF VIROLOGY, 1990, 64 (05) :2337-2344
[8]   Chemokine receptors and HIV [J].
Broder, CC ;
Collman, RG .
JOURNAL OF LEUKOCYTE BIOLOGY, 1997, 62 (01) :20-29
[9]   SPECIFIC CELL-SURFACE REQUIREMENTS FOR THE INFECTION OF CD4-POSITIVE CELLS BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2 AND BY SIMIAN IMMUNODEFICIENCY VIRUS [J].
CLAPHAM, PR ;
BLANC, D ;
WEISS, RA .
VIROLOGY, 1991, 181 (02) :703-715
[10]   Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4(+) cell lines [J].
Decroly, E ;
Wouters, S ;
DiBello, C ;
Lazure, C ;
Ruysschaert, JM ;
Seidah, NG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (48) :30442-30450